PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

DHSC publishes ‘UK Rare Disease Framework’

The UK’s Department of Health and Social Care (DHSC) has published its ‘UK Rare Disease Framework’, which will aim to continuously improve the lives of people living with rare diseases.

Despite rare diseases being individually uncommon, it is currently estimated that there are over 7,000 rare disease, with new conditions being identified as research advances.

Currently, 1 in 17 people will be affected by a rare disease at some point during their lifetime.

The framework identifies four key priorities for rare diseases care and diagnosis to be addressed over the next five years, which includes:

  1. Helping patients get a final diagnosis faster
  2. Increase awareness of rare disease among healthcare professionals
  3. Supporting better coordination of care
  4. Improving access to specialist care, treatment and drugs.

The framework will seek to work with the four nations of the UK to improve patient care for people living with rare diseases, building on the prior commitments made in the UK Strategy for Rare Diseases.

The four key priorities are also supported by further ‘underpinning themes’, which are identified as: patient voice; national and international collaboration; pioneering research; digital, data and technology; and wider policy alignment.

“We welcome the publication of the UK Rare Diseases Framework and look forward to working with the four nations of the UK to help to deliver its aims,” said Nick Meade, Genetic Alliance UK – part of Rare Disease UK.

“This is once again an almost unique piece of health policy in that it represents a commitment from four health ministers from across the UK to deliver a shared aim for people living with rare conditions,” he added.

Following the publication of the new framework, the four nations of the UK will now develop action plans to identify how they will address the four key priorities laid out above.

These action plans will be published, where possible, in 2021, according to the UK Rare Disease Framework document.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026